
Efferent Labs Applauds FDA’s Shift Away from Animal Testing
Efferent Labs’ CytoComm® platform is positioned as a critical enabler of new drug evaluation standards following the FDA’s shift from animal testing. MOUNT PLEASANT, SC, UNITED STATES, April 17, 2025 /EINPresswire.com/ -- Efferent Labs, Inc., a …